<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04479813</url>
  </required_header>
  <id_info>
    <org_study_id>REG 15-021</org_study_id>
    <nct_id>NCT04479813</nct_id>
  </id_info>
  <brief_title>Role of Sympathetic Activation in Ischemia Reperfusion Injury</brief_title>
  <official_title>Role of Sympathetic Activation in Ischemia Reperfusion Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Perth Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Perth Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the effect of forearm ischemia-reperfusion injury on
      sympathetic nerve activity. To determine whether reduced sympathetic responsiveness is a
      contributor to the protective effects of remote ischemic preconditioning. In addition it will
      assess whether pharmacologic inhibition of the sympathetic nervous system can ameliorate
      ischemia reperfusion injury induced endothelial dysfunction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized single blind study where subjects will be allocated to undergo one of
      the 4 protocols. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20
      minutes prior to the first endothelial function measurement.

      This medication acts by reducing the activity of nerves believed to be involved in the
      conditioning process. The placebo pill, designed to have no effect, will be used as a
      comparison. Comprehensive tests will occur which include Microneurography, Endothelial
      function ,Blood Sampling, Temporary block of arm blood flow and Remote conditioning
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in muscle sympathetic nerve activity</measure>
    <time_frame>1 day</time_frame>
    <description>Muscle sympathetic nerve activity assessed by microneurography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endothelial Function using the EndoPat2000 device</measure>
    <time_frame>2 days</time_frame>
    <description>Endothelial Function testing involves the measurement of pulse amplitude from the tip of each index finger at rest and after a period of occlusion using an arm cuff that is manually inflated to a level above that of the participant's Blood Pressure (BP).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Central Sympathetic Nervous System</condition>
  <arm_group>
    <arm_group_label>No conditioning + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given placebo to take orally 20 minutes prior to the first endothelial function measurement without conditioning tests.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No conditioning + moxonidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given moxonidine to take orally 20 minutes prior to the first endothelial function measurement without conditioning tests.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remote pre-conditioning + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given placebo to take orally 20 minutes prior to the first endothelial function measurement with conditioning tests.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remote pre-conditioning + moxonidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given moxonidine to take orally 20 minutes prior to the first endothelial function measurement with conditioning tests.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxonidine 0.2 MG</intervention_name>
    <description>Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.</description>
    <arm_group_label>No conditioning + moxonidine</arm_group_label>
    <arm_group_label>Remote pre-conditioning + moxonidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.</description>
    <arm_group_label>No conditioning + placebo</arm_group_label>
    <arm_group_label>Remote pre-conditioning + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy males, not on any medication, free of any history of metabolic, cardiovascular
             or cerebrovascular disease.

        Exclusion Criteria:

          -  smoker
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>50 healthy male volunteers (25 aged 18-30 years and 25 aged 60-75 years)</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Schlaich, MD,FAHA,FESC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Perth Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anu Joyson, MSN</last_name>
    <phone>+61 8 92240390</phone>
    <email>anu.joyson@uwa.edu.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Revathy Carnagarin, MD</last_name>
    <phone>92240316</phone>
    <email>revathy.carnagarin@uwa.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dobney Hypertension Centre</name>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Schlaich</last_name>
      <phone>+61 8 92240390</phone>
    </contact>
    <contact_backup>
      <last_name>Revathy Carnagarin</last_name>
      <phone>+61 8 92240316</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 16, 2020</study_first_submitted>
  <study_first_submitted_qc>July 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2020</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Royal Perth Hospital</investigator_affiliation>
    <investigator_full_name>Dr Markus Schlaich</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Ischemia</keyword>
  <keyword>re-perfusion</keyword>
  <keyword>Remote conditioning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reperfusion Injury</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxonidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

